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ABSTRACT
Background: Whole genome sequencing (WGS) is a powerful method for revealing the diversity and 
complexity of the somatic mutation burden of tumours. Here we investigated the utility of tumour 
and matched germline WGS for understanding aetiology and treatment opportunities for high-risk 
individuals with familial breast cancer.
Patients and Methods: We carried out WGS on 78 paired germline and tumour DNA samples from 
individuals carrying pathogenic variants in BRCA1 (n = 26) or BRCA2 (n = 22) or from non-carriers (non-
BRCA1/2; n = 30).
Results: Matched germline/tumour WGS and somatic mutational signature analysis revealed patients 
with unreported, dual pathogenic germline variants in cancer risk genes (BRCA1/BRCA2; 
BRCA1/MUTYH). The strategy identified that 100% of tumours from BRCA1 carriers and 91% of 
tumours from BRCA2 carriers exhibited biallelic inactivation of the respective gene, together with 
somatic mutational signatures suggestive of a functional deficiency in homologous recombination. A 
set of non-BRCA1/2 tumours also had somatic signatures indicative of BRCA-deficiency; including 
carriers of a PALB2 pathogenic germline variant and a BRCA2 variant of uncertain significance (VUS). 
A subset of 13 non-BRCA1/2 tumours from early onset cases were BRCA-proficient, yet displayed 
complex clustered structural rearrangements associated with the amplification of oncogenes and 
pathogenic germline variants in TP53, ATM and CHEK2.
Conclusions: Our study highlights the role that WGS of matched germline/tumour DNA and the 
somatic mutational signatures can play in the discovery of pathogenic germline variants and for 
providing supporting evidence for variant pathogenicity. WGS-derived signatures were more robust 
than germline status and other genomic predictors of homologous recombination deficiency, thus 
impacting the selection of platinum-based or PARP inhibitor therapy. In this first examination of non-
BRCA1/2 tumours by WGS, we illustrate the considerable heterogeneity of these tumour genomes 
and highlight that complex genomic rearrangements may drive tumourigenesis in a subset of cases.
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KEY MESSAGE: We demonstrate the role for matched germline/tumour whole genome sequencing 
and somatic mutational signatures to give insight into the aetiology of high-risk familial breast cancer. 
We illustrate how the approach can improve the diagnosis and management of individuals and their 
families by clarifying germline pathogenicity and enhancing the selection of platinum-based or PARP 
inhibitor therapy.
WORD COUNT: 3884 (Intro to conclusions= 2448; References=836, Figures x 4 =600).
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INTRODUCTION
Approximately 15-20% of breast cancers (BC) are associated with a strong family history of the disease. 
Pathogenic variants in BRCA1, BRCA2 or other moderate to highly penetrant susceptibility genes (e.g. 
TP53, ATM, CHEK2, PALB2 and PTEN) account for <50% of familial BC and thus for the majority of 
families the underlying genetic contribution to their cancer risk remains unknown. Approximately 10% 
of individuals may benefit from the identification of germline pathogenic variants using multigene 
panel sequencing, however little insight is gained for a large number of individuals and there is an 
increasing identification of VUS [1]. Germline testing is also impacting therapy, since carriers of 
germline pathogenic BRCA1/2 variants derive enhanced benefit from platinum-based chemotherapy 
or Poly(ADP-ribose) polymerase inhibitors (PARPi) [2-7].
WGS detects a broad repertoire of somatic and/or germline alterations in an unbiased manner. The 
frequency and distribution of somatic mutations serve as an imprint, or signature, of mutational 
processes or exposures that contribute to tumour development [8-10]. Some somatic mutational 
signatures are strongly linked to pathogenic germline variants in risk genes that play functional roles 
in DNA repair; for instance, homologous recombination (HR; BRCA1, BRCA2), mismatch repair (MLH1, 
MSH2, MSH6) or base excision repair (MUTYH) [7-9, 11]. In BC, 12 substitution and six structural 
rearrangement signatures were identified [9]. The combination of these signatures was used to 
develop HRDetect, a robust predictor of BRCA-deficiency and hence PARPi benefit [7]. 
METHODS
We analysed 78 tumours from high-risk familial BC patients to investigate how WGS could impact the 
management of both risk and therapy for individuals and their families. Cases were carriers of a BRCA1 
pathogenic germline variant (n = 26), a BRCA2 pathogenic germline variant (n = 22) or neither (non-
BRCA1/2, n = 30)(Supplementary Table S1). In order to characterise the somatic landscape of these 
cases, matched germline/tumour DNA underwent WGS using Illumina X-Ten sequencing to an average 
6
fold depth of 34x and 68x, respectively. WGS data was analysed to characterise somatic mutations 
(single nucleotide variants, insertions-deletions, structural variants, copy number), mutational 
signatures and measures of HR-deficiency (HRDetect, HRD Index) (Supplementary Table S2). This 
approach highlighted important mechanisms of genomic instability that underly familial breast cancer.
Please refer to “Online Supplementary Material” for details.
RESULTS
Somatic Landscape of Familial Breast Cancer
The somatic mutational landscape differed between tumours from BRCA1, BRCA2 and non-BRCA1/2 
carriers (Figure 1, Supplementary Figure S1). Seventy-nine out of 93 previously identified BC driver 
genes [9] were mutated; including a high frequency of mutations in TP53 (88%) in BRCA1-tumours and 
GATA3/PIK3CA (50%) in non-BRCA1/2-tumours (Supplementary Figure S2, Tables S3-S4). BRCA1- and 
BRCA2-tumours harboured more small deletions and single nucleotide variants (SNVs) compared with 
non-BRCA1/2 tumours; and BRCA1-tumours exhibited a higher number of structural rearrangements 
including duplications and translocations compared with BRCA2 and non-BRCA1/2 tumours (both 
p≤0.001, Mann-Whitney U-test). 
Five substitution and five rearrangement signatures [8, 9] were identified (Figure 2, Supplementary 
Figure S3). BRCA1-tumours had the highest proportion of substitution signature 3 and rearrangement 
signature 3; while BRCA2-tumours had the highest burden of substitution signature 8 and 
rearrangement signature 5 (both p≤0.001, Mann-Whitney U-test). 
The mutation profile of non-BRCA1/2-tumours was diverse, suggesting a likely heterogeneous 
aetiology. Tumours had: 1) quiet genomes with few somatic mutations, 2) a high SNV burden 
associated with APOBEC substitution signature [8], 3) a high burden of rearrangement signature 4 
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(clustered rearrangements), or 4) mutational signatures suggesting BRCA1/2 deficiency (Figures 1-2, 
Supplementary Figures S1-S3, Table S2).
Somatic mutational signatures to stratify tumours
Unsupervised hierarchical clustering based on the contribution of multiple mutational signatures in 
each tumour stratified the cohort into three groups that broadly captured germline status, hence 
these groups were termed ‘BRCA1-like’, ‘BRCA2-like’ or ‘non-BRCA1/2-like’ (Figure 3). Ten tumours 
(13%) clustered away from their ‘original BRCA status’, including two BRCA1-, two BRCA2- and six non-
BRCA1/2-tumours. All tumours stratified as ‘non-BRCA1/2-like’ were BRCA-proficient (HRDetect 
scores <0.7), while all ‘BRCA1-like’ and ‘BRCA2-like’ tumours were BRCA-deficient (Figure 3, 
Supplementary Figure S4, Table S2).  We show that the combination of multiple mutational signatures 
or HRDetect[7] enabled better classification of the HR status in tumours than when using individual 
mutational signatures alone (Figure 3, Supplementary Figure S4).
WGS characteristics of tumours with ‘BRCA1-like’ mutational signatures
Twenty-nine tumours showed ’BRCA1-like’ mutational signatures; all had biallelic inactivation of 
BRCA1 and were BRCA-deficient according to HRDetect. Most tumours were Grade-3 and triple-
negative, but included two histological Grade-2, four ER/PR positive and three HER2 positive tumours 
(Figure 3).
Previously undetected carriers of dual germline pathogenic variants were discovered by WGS-derived 
mutational signatures. Case FBC090235 carried a BRCA2 germline pathogenic variant 
(c.574_575delAT; p.Met192ValfsX13) identified by germline testing. WGS revealed only mono-allelic 
loss of BRCA2 but also a BRCA1 germline structural rearrangement (chr17:g.41230286_41236428dup) 
coupled with somatic loss of the wild-type allele (Figure 3, Supplementary Figure S5). Case FBC070205 
carried a BRCA1 germline pathogenic variant (c.5244_5245delAA; p.Lys1748fs) and somatic loss of the 
8
wild-type allele, and the tumour showed a high contribution of the somatic rearrangement signature 
3. However, substitution signatures were dominated by C>A transversions in NpCpA or NpCpT 
contexts (Figures 2-3) previously associated with inactivation of the BER gene MUTYH [11]. We 
subsequently identified a MUTYH germline pathogenic variant (c.1556G>A; p.Arg519Gln) and somatic 
loss of the wild-type allele (Supplementary Figure S6). The biallelic inactivation of both genes, 
together with evidence of their mutational signatures suggest that both genes contributed to 
tumourigenesis. 
Four non-BRCA1/2-tumours harboured mutational signatures suggestive of BRCA1 loss-of-function 
(cases FBC020021, FBC040626, FBC060116, FBC050467) (Figure 3). Each tumour had somatic LOH of 
BRCA1 and three exhibited somatic BRCA1 promoter methylation (case FBC050467 had insufficient 
tumour DNA for methylation assessment). BRCA1 promoter methylation was tested in the blood of all 
four cases and other family members, but all were found to be unmethylated, suggesting that these 
tumours are likely driven by somatic biallelic inactivation of BRCA1 (Supplementary Figure S7). We 
found no evidence of biallelic inactivation of 52 additional genes involved in the HR pathway [12] that 
could account for the HR defective signatures (Supplementary Tables S3-S6).
WGS characteristics of tumours with ‘BRCA2-like’ mutational signatures
Twenty-four tumours contained ‘BRCA2-like’ signatures and all were BRCA1/2 deficient according to 
HRDetect. This group included 20 of the 22 BRCA2-tumours, each with biallelic inactivation of BRCA2; 
19 ER/PR positive tumours, nine Grade-2 tumours and two invasive lobular carcinomas (Figure 3).
WGS of non-BRCA1/2 case FBC020031 confirmed the previously identified PALB2 nonsense variant 
(rs180177132; c.3113G>A p.Trp1038*) and detected somatic loss of the wild-type allele. The tumour 
was ‘BRCA2-like’ with a high burden of substitution signature 3 and rearrangement signature 5 
supporting previous studies linking loss of PALB2 function with BRCA-deficient signatures [7, 10, 13]. 
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Non-BRCA1/2 case FBC060681 harboured a BRCA2 VUS (c.7828G>A p.Val2610Met). The tumour 
presented somatic loss of the wild-type allele, as well as ‘BRCA2-like’ mutational signatures. The 
variant was not reported in gnomAD or in the 560 BC genomes cohort [9], and is described by ClinVar 
(Variation ID: 135816) as ‘Class 3 Uncertain significance’ (Supplementary Table S5). The variant is in a 
highly conserved amino acid and is predicted to create a de novo donor splice-site in exon 17, although 
no experimental evidence supported this [14]. Protein modelling of the variant predicted a damaging 
effect on protein structure and function (Supplementary Figure S8). No evidence of biallelic 
inactivation in 52 HR-related genes [12] were identified in this case (Supplementary Tables S3-S6). 
WGS characteristics of tumours with ‘non-BRCA1/2-like’ mutational signatures
Twenty-five tumours were classified as ‘non-BRCA1/2-like’ and included 24 tumours from non-
BRCA1/2 cases and a BRCA2-tumour (FBC016006, NM_000059.3, c.1310_1313delAAGA) that lacked 
somatic inactivation of the BRCA2 wild-type allele (Supplementary Figure S9). Twenty-two tumours 
were ER/PR positive; six were HER2 positive; and all were considered BRCA-proficient (Figure 3). Case 
FBC070169 had a strong APOBEC substitution signature accounting for 94% of the somatic mutations, 
yet there was no evidence of the APOBEC3A or APOBEC3B germline variants previously associated 
with this signature [15, 16].
Unsupervised hierarchical clustering stratified the ‘non-BRCA1/2-like’ tumours into two groups based 
on the contributions of rearrangement signatures 1, 2 and 4 (Figures 3-4, Supplementary Figure S10). 
Twelve tumours had either relatively quiet genomes dominated by rearrangement signature 2 (n=9; 
with recurrent gain of 1q and/or loss of 16q) or rearrangement signature 1 (n=3). The remaining 
thirteen tumours were younger at diagnosis (median age 44 vs. 62 years) and displayed a high 
contribution of rearrangement signature 4, involving complex rearrangements clustered to one or a 
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few chromosomes. These clustered events coincided with amplifications of known BC oncogenes (e.g. 
ZNF217, ERBB2, CCND1, MYC) [9], and in 8/13 tumours, the patterns of rearrangements suggested 
evidence for Breakage-Fusion-Bridge (BFB) cycles; two additional tumours had events resembling 
chromothripsis and BFB (Figure 4). We observed that ‘non-BRCA1/2-like’ tumours had shorter 
telomeres than BRCA-deficient tumours (Supplementary Figure S11) raising the possibility that 
dicentric chromosome formation due to telomeric erosion could lead to BFB and/or chromothripsis 
[17, 18]. We were unable to identify germline or somatic variants in candidate genes associated with 
chromosomal segregation or telomere maintenance that could potentially lead to this pattern of 
rearrangements. In four cases, however, we identified rare germline variants in TP53 
(NM_000546.5:c.1009C>T), ATM (NM_000051.3:c.4909+1G>A) and CHEK2 (NM_007194.3:c.349A>G; 
NM_007194.3:c.1100delC), together with somatic loss of the wild-type allele, implying functional loss 
of the relevant protein (Figure 4). 
DISCUSSION
This study represents the largest cohort of familial BC cases examined by WGS, and the first report 
from high-risk, non-BRCA1/2 families. The findings demonstrate the impact that combined germline 
and somatic WGS can offer as a companion diagnostic in clarifying cancer risk in individuals and in 
aiding decisions regarding treatment. We confirm the importance of biallelic inactivation of germline 
risk genes to drive the accumulation of specific patterns of somatic mutational signatures. Loss of 
function of BRCA1, BRCA2 and PALB2 yield a high mutation burden and specific signatures inferring 
defective HR [7, 9, 10 , 13]. Despite the role of TP53, ATM and CHEK2 in DNA-damage signalling and 
double-strand breaks detection, these tumours do not show evidence of BRCA-deficient signatures, 
as previously described [9, 13, 19], but instead they harbour highly complex clustered chromosomal 
rearrangements.
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WGS-derived signatures identified two individuals as carriers of dual germline pathogenic variants 
(BRCA1/BRCA2 and BRCA1/MUTYH), which were previously unreported. Mutation signatures 
indicated that biallelic inactivation of BRCA1 rather than BRCA2 was driving tumorigenesis in the 
BRCA1/BRCA2 case. Clinical BRCA1 and BRCA2 testing (in 2004) identified a pathogenic BRCA2 
germline variant (c.574_575delAT; Met192ValfsX13), thus further testing was not pursued. During this 
study, a family member diagnosed with BC was found not to carry this variant, and more extensive 
testing revealed the BRCA1 germline rearrangement. Segregation of disease in the BRCA1/BRCA2 
family was incomplete until the BRCA1 rearrangement was considered. Co-occurring germline 
pathogenic variants in BRCA1 and BRCA2 are rare (0.3%, 93/32,295 cases) and carriers are more likely 
to be diagnosed with BC than BRCA1 or BRCA2 only carriers [20]. Little is known about incidence and 
risk profile for BRCA1/MUTYH carriers, and biospecimens from other family members were 
unavailable, so it was unclear how the variants segregate with disease. However, it is clear that biallelic 
inactivation of both genes contributed to tumorigenesis. These cases exemplify the importance of 
thorough germline testing and the power of WGS as a single test to i) screen entire genes for different 
types of variants (SNV and rearrangements); and ii) derive somatic mutational signatures for both 
variant discovery and delineating the aetiology of disease. 
Several lines of evidence support that the BRCA2 VUS (c.7828G>A p.Val2610Met) contributed to 
tumorigenesis: 1) somatic biallelic inactivation of BRCA2 (VUS and LOH); 2) the tumour was ‘BRCA2-
like’ according to the pattern of mutation signatures and was BRCA-deficient according to HRDetect; 
3) no variants were identified in other HR pathway genes that could explain this BRCA-deficiency; and 
4) protein modelling predicted a negative impact on protein function. This rare variant has only been 
described once in the literature [14], evaluating the same individual as reported here. Further 
investigation of the pathogenicity of this rare p.Val2610Met variant is warranted. 
12
Most familial BC fall under the umbrella term of non-BRCA1/2, involving germline variants in other 
moderate- to highly-penetrant genes, or where the underlying genetic cause is unknown. Non-
BRCA1/2 tumours exhibit considerable morphological [21], molecular [22] and genomic 
heterogeneity. WGS provided evidence regarding the drivers of tumorigenesis in many cases, 
including germline carriers of variants in BRCA2 (VUS), PALB2, CHEK2, ATM and TP53; BRCA1 promoter 
methylation, APOBEC mutagenesis, and oncogene amplification. 
The subgroup of ‘non-BRCA1/2-like’ tumours harbouring complex patterns of clustered structural 
rearrangements, were early onset cancers with an ER-positive and/or HER2-positive phenotype. The 
complex rearrangements were associated with amplification of various oncogenes and showed 
evidence of BFB and chromothripsis as a potential mechanism driving tumorigenesis [18]. Four cases 
within this group harboured germline pathogenic variants in ATM [23], CHEK2 [24] or TP53 [25], all 
with somatic LOH. Chromothripsis and BFB have been reported in numerous tumour types, and 
intriguingly, germline variants in ATM and TP53 were associated with such complex structural 
rearrangements in acute lymphoblastic leukemia [26] and medulloblastoma [27]. Whilst these 
patterns of rearrangements have been reported in BC [28, 29], they have not been associated with a 
germline predisposition. Interestingly, >60% of BC in germline TP53 carriers are ERBB2/HER2 amplified 
[30] and complex structural rearrangements are suggested to drive amplification in such cancers [29].
Better predicting response to therapy is critical to advance oncology. Investigators have used various 
means to improve the utility of DNA-damaging chemotherapies and PARPi, for instance: the germline 
status of BRCA1 or BRCA2; somatic LOH of these genes; a triple-negative tumour phenotype; or 
patterns of somatic mutations [2-7]. We confirm the utility of WGS and HRDetect [7] to enhance the 
stratification of tumours as being BRCA-proficient versus deficient compared to individual genomic 
parameters (e.g. HRD score and substitution signature 3). Using this approach, all BRCA1-tumours, 
91% of BRCA2-tumours and the PALB2 tumour had bialleic inactivation of said gene and strong 
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evidence of HR-deficiency. These cases would be predicted to be good candidates for platinum-based 
chemotherapy or PARPi, and included 12 tumours that would not otherwise fall into this 
recommendation of treatment (i.e. histological Grade-2, ER/PR positive [31], or invasive lobular 
carcinoma). In contrast to a recent report, only two tumours (2/22, 9% versus 46% [5]) from BRCA2 
carriers did not exhibit biallelic inactivation of the gene; one tumour was BRCA-deficient due to the 
biallelic inactivation of BRCA1, whereas the other was BRCA-proficient, and hence this latter patient 
would be unlikely to benefit from such therapies. 
In summary, matched germline/tumour WGS can improve the identification of the underlying genetic 
cause of disease over BRCA1 and BRCA2 germline screening alone and that this will likely improve the 
clinical management of individuals and potentially their families. Furthermore, WGS yields the most 
robust assessment of BRCA deficiency and can also identify oncogenic drivers in BRCA-proficient 
tumours, which collectively may enhance the selection of targeted therapies for patients.
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FIGURE LEGENDS
Figure 1. Somatic mutational landscape of 78 familial breast cancers grouped by BRCA status 
determined by original clinical diagnosis. a) Clinical information for each sample includes: germline 
pathogenic variant status from clinical testing of BRCA1 and BRCA2 genes, gender, age at diagnosis, 
tumour morphological type, histological grade and biomarker status for estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). b) The number of 
somatic indels per sample; insertions in red and small deletions in blue. c) Number of somatic single 
nucleotide variants (SNVs). d) Number and type of somatic structural rearrangements: duplications 
(green), deletions (orange), inversions (blue) and translocations (grey). Abbreviations: IC NST – 
Invasive Carcinoma No Special Type; MDL – Mixed Ductal-Lobular Carcinoma; DCIS – Ductal Carcinoma 
In Situ; ILC – Invasive Lobular Carcinoma; Med. Ca. – Medullary Carcinoma; Met. Ca – Metaplastic 
Carcinoma; Muc. Ca. – Mucinous Carcinoma; # - number; n/a – not available.
Figure 2. Somatic mutational signatures in familial breast cancer. a) Five substitution mutational 
signatures were identified and cosine similarity was used to compare the signatures to known 
signatures in COSMIC (signatures were assigned based on highest similarity). b) Five somatic 
rearrangement signatures were identified and cosine similarity was used to compare to 
rearrangement signatures previously reported in breast cancers [9]. Rearrangements were grouped 
as clustered in the genome or not, then grouped by type: deletion (Del), duplication (Dup), inversion 
(Inv) or translocations (T); and then by size (as indicated on the x axis). c) The proportion of each 
substitution signature present per tumour (see colour coding in legend): Tumours from BRCA1 carriers 
had a higher proportion of substitution signature 3 (orange); tumours from BRCA2 carriers had a 
higher proportion substitution signature 8 (purple); tumours from non-BRCA1/2 cases had 
heterogeneous patterns of signatures, but a high proportion of substitution signature 1 (previously 
associated with age; green). One tumour had a dominant signature 18 (MUTYH, blue) and one tumour 
had a prominent signature 13 (APOBEC, red). d) The proportion of each rearrangement signature per 
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tumour (see colour coding in legend): Tumours from BRCA1 carriers had a higher proportion of 
rearrangement signature 3 (blue), tumours from BRCA2 carriers had higher proportion of 
rearrangement signature 5 (light blue); tumours from non-BRCA1/2 cases had heterogeneous patterns 
of rearrangement signatures, but the highest proportion of rearrangement signatures 4 (green) and 2 
(purple). 
Figure 3. Stratification of tumour using unsupervised hierarchical clustering of the somatic 
mutational signatures. a) Hierarchical clustering of the somatic genomic characteristics was based on 
the percentage contribution of each mutational signature per tumour (see colour coding at bottom), 
the ratio of insertion to deletions, and the HRD index [3, 4] using the Euclidean method for dissimilarity 
matrix and Ward.D2 for hierarchical clustering. Tumours were stratified into three groups based 
mainly on BRCA status (germline carriers of BRCA1 or BRCA2 or non-BRCA1/2) and so the three groups 
were termed ‘BRCA1-like’, ‘BRCA2-like’ or ‘non-BRCA1/2-like’. b) Number of mutation in each tumour, 
including insertion and deletions, SNVs and structural rearrangements coloured by the number of 
mutations associated with the different mutational signatures.  c) Panel shows HRDetect scores [7] 
(the cutoff for HR deficiency in the original study > 0.7; all BRCA1-like and BRCA2-like tumours had a 
score >0.99) and the presence of pathogenic germline variants and/or somatic alterations observed 
in BRCA1 or BRCA2. d) Clinical information and tumour features according to Figure 1, together with 
tumour codes for cases discussed in text. e) Examples of circos plots from each subgroup showing 
characteristic patterns of structural rearrangements. From the left: FBC050727 (non-BRCA1/2), 
FBC070474 (clustered rearrangements), FBC061542 (BRCA2 biallelic inactivation), FBC020031 (PALB2 
biallelic inactivation), FBC060031 (BRCA1 biallelic inactivation), FBC060116 (BRCA1 promoter 
methylation/LOH). Abbreviations: VUS - variant of unknown clinical significance;  LOH – loss of 
heterozygosity; n/a – not available. 
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Figure 4. Whole-genome DNA copy number profile of non-BRCA1/2-like tumours. a) Arm level copy 
number data (gains (red) and losses (blue)) across the genome in non-BRCA1/2-like tumours stratified 
according to rearrangement signatures 1, 2 and 4. Tumours are plotted in the same order as Figure 3. 
Tumours are identified which: harbour germline pathogenic variants in risk genes ATM, TP53 or 
CHEK2; show evidence of Break-fusion bridge and/or chromothripsis; and harbour amplification of 
various oncogenes. b) Circos plots are shown for the cases with germline variants in ATM, TP53 and 
CHEK2. Non-BRCA1/2-like tumours with a high proportion of rearrangement signature 4 (clustered 
rearrangements) were: c) diagnosed at a significantly younger age to non-BRCA1/2 tumours with other 
genome characteristics (Mann Whitney U-test, two-tailed); but d) the distribution of histological grade 
was not significantly different (Chi-square).
 
Figure 1. Somatic mutational landscape of 78 familial breast cancers grouped by BRCA status determined by 
original clinical diagnosis. a) Clinical information for each sample includes: germline pathogenic variant 
status from clinical testing of BRCA1 and BRCA2 genes, gender, age at diagnosis, tumour morphological 
type, histological grade and biomarker status for estrogen receptor (ER), progesterone receptor (PR) and 
human epidermal growth factor receptor 2 (HER2). b) The number of somatic indels per sample; insertions 
in red and small deletions in blue. c) Number of somatic single nucleotide variants (SNVs). d) Number and 
type of somatic structural rearrangements: duplications (green), deletions (orange), inversions (blue) and 
translocations (grey). Abbreviations: IC NST – Invasive Carcinoma No Special Type; MDL – Mixed Ductal-
Lobular Carcinoma; DCIS – Ductal Carcinoma In Situ; ILC – Invasive Lobular Carcinoma; Med. Ca. – 
Medullary Carcinoma; Met. Ca – Metaplastic Carcinoma; Muc. Ca. – Mucinous Carcinoma; # - number; n/a – 
not available. 
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Figure 2. Somatic mutational signatures in familial breast cancer. a) Five substitution mutational signatures 
were identified and cosine similarity was used to compare the signatures to known signatures in COSMIC 
(signatures were assigned based on highest similarity). b) Five somatic rearrangement signatures were 
identified and cosine similarity was used to compare to rearrangement signatures previously reported in 
breast cancers [9]. Rearrangements were grouped as clustered in the genome or not, then grouped by type: 
deletion (Del), duplication (Dup), inversion (Inv) or translocations (T); and then by size (as indicated on the 
x axis). c) The proportion of each substitution signature present per tumour (see colour coding in legend): 
Tumours from BRCA1 carriers had a higher proportion of substitution signature 3 (orange); tumours from 
BRCA2 carriers had a higher proportion substitution signature 8 (purple); tumours from non-BRCA1/2 cases 
had heterogeneous patterns of signatures, but a high proportion of substitution signature 1 (previously 
associated with age; green). One tumour had a dominant signature 18 (MUTYH, blue) and one tumour had a 
prominent signature 13 (APOBEC, red). d) The proportion of each rearrangement signature per tumour (see 
colour coding in legend): Tumours from BRCA1 carriers had a higher proportion of rearrangement signature 
3 (blue), tumours from BRCA2 carriers had higher proportion of rearrangement signature 5 (light blue); 
tumours from non-BRCA1/2 cases had heterogeneous patterns of rearrangement signatures, but the highest 
proportion of rearrangement signatures 4 (green) and 2 (purple). 
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Figure 3. Stratification of tumour using unsupervised hierarchical clustering of the somatic mutational 
signatures. a) Hierarchical clustering of the somatic genomic characteristics was based on the percentage 
contribution of each mutational signature per tumour (see colour coding at bottom), the ratio of insertion to 
deletions, and the HRD index [3, 4] using the Euclidean method for dissimilarity matrix and Ward.D2 for 
hierarchical clustering. Tumours were stratified into three groups based mainly on BRCA status (germline 
carriers of BRCA1 or BRCA2 or non-BRCA1/2) and so the three groups were termed ‘BRCA1-like’, ‘BRCA2-
like’ or ‘non-BRCA1/2-like’. b) Number of mutation in each tumour, including insertion and deletions, SNVs 
and structural rearrangements coloured by the number of mutations associated with the different mutational 
signatures.  c) Panel shows HRDetect scores [7] (the cutoff for HR deficiency in the original study > 0.7; all 
BRCA1-like and BRCA2-like tumours had a score >0.99) and the presence of pathogenic germline variants 
and/or somatic alterations observed in BRCA1 or BRCA2. d) Clinical information and tumour features 
according to Figure 1, together with tumour codes for cases discussed in text. e) Examples of circos plots 
from each subgroup showing characteristic patterns of structural rearrangements. From the left: FBC050727 
(non-BRCA1/2), FBC070474 (clustered rearrangements), FBC061542 (BRCA2 biallelic inactivation), 
FBC020031 (PALB2 biallelic inactivation), FBC060031 (BRCA1 biallelic inactivation), FBC060116 (BRCA1 
promoter methylation/LOH). Abbreviations: VUS - variant of unknown clinical significance;  LOH – loss of 
heterozygosity; n/a – not available. 
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Figure 4. Whole-genome DNA copy number profile of non-BRCA1/2-like tumours. a) Arm level copy number 
data (gains (red) and losses (blue)) across the genome in non-BRCA1/2-like tumours stratified according to 
rearrangement signatures 1, 2 and 4. Tumours are plotted in the same order as Figure 3. Tumours are 
identified which: harbour germline pathogenic variants in risk genes ATM, TP53 or CHEK2; show evidence of 
Break-fusion bridge and/or chromothripsis; and harbour amplification of various oncogenes. b) Circos plots 
are shown for the cases with germline variants in ATM, TP53 and CHEK2. Non-BRCA1/2-like tumours with a 
high proportion of rearrangement signature 4 (clustered rearrangements) were: c) diagnosed at a 
significantly younger age to non-BRCA1/2 tumours with other genome characteristics (Mann Whitney U-test, 
two-tailed); but d) the distribution of histological grade was not significantly different (Chi-square). 
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